Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen

Ann Neurol. 1996 Jan;39(1):136-9. doi: 10.1002/ana.410390121.

Abstract

In this study, we preincubated the sera of 3 patients with neuropathies associated with elevated titers of IgM anti-GM1 antibodies, with increasing concentrations of intravenous Ig (IVIg) and assayed the inhibitory effect of this mixture on antibody binding to immobilized GM1 by an enzyme-linked immunosorbent assay. Pharmacologic concentrations of IVIg, ranging from 0.1 microgram/ml to 100 mg/ml, inhibited anti-GM1 binding to its target antigen from 26 +/- 3 to 71 +/- 7%, respectively, in a dose-dependent manner. A similar inhibition of binding was also observed with IVIg F(ab')2 fragments. These findings provide a possible mechanism for the clinical efficacy of IVIg in motor neuropathies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • G(M1) Ganglioside / immunology
  • G(M1) Ganglioside / metabolism*
  • Humans
  • Immunoglobulin M / blood
  • Immunoglobulin M / metabolism*
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / pharmacology*
  • Motor Neuron Disease / immunology*
  • Motor Neuron Disease / therapy*
  • Protein Binding / drug effects
  • gamma-Globulins / administration & dosage
  • gamma-Globulins / pharmacology*

Substances

  • Immunoglobulin M
  • Immunoglobulins, Intravenous
  • gamma-Globulins
  • G(M1) Ganglioside